Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To evaluate long-term efficacy and safety of pregabalin (150 to 600mg/day) as adjunctive treatment in patients with partial seizures.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Single Arm | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Pregabalin | Drug | Pregabalin |
|
| Measure | Description | Time Frame |
|---|---|---|
| Reduction in seizure frequency. | 18 months |
| Measure | Description | Time Frame |
|---|---|---|
| Seizure-free patients during each 3-month period | 18 Months | |
| Responder Rate 50% during each 3-month period (proportion of patients with 50% or greater reduction of seizures). | 18 Months | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | Bruges | B-8000 | Belgium | |||
| Pfizer Investigational Site |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Responder rate 75% during each 3-month period (proportion of patients with 75% or greater reduction of seizures). |
| 18 Months |
| Brussels |
| 1070 |
| Belgium |
| Pfizer Investigational Site | Duffel | B-2570 | Belgium |
| Pfizer Investigational Site | Ghent | 9000 | Belgium |
| Pfizer Investigational Site | Leuven | B-3000 | Belgium |
| Pfizer Investigational Site | Liège | 4000 | Belgium |
| Pfizer Investigational Site | Tielt | B-8700 | Belgium |
| Pfizer Investigational Site | Yvoir | 5530 | Belgium |
| Pfizer Investigational Site | Helsinki | 00250 | Finland |
| Pfizer Investigational Site | Kuopio | 70210 | Finland |
| Pfizer Investigational Site | Tampere | 33520 | Finland |
| Pfizer Investigational Site | Paris | Cedex 14 | 75674 | France |
| Pfizer Investigational Site | Lille | Cedex | 59037 | France |
| Pfizer Investigational Site | Lyon | Cedex | 69694 | France |
| Pfizer Investigational Site | Marsille | Cedex | 13385 | France |
| Pfizer Investigational Site | Rennes | Cedex | 35033 | France |
| Pfizer Investigational Site | Bayonne | 64109 | France |
| Pfizer Investigational Site | Bordeaux | 33076 | France |
| Pfizer Investigational Site | Grenoble | 38043 | France |
| Pfizer Investigational Site | Marseille 13 | 13009 | France |
| Pfizer Investigational Site | Montpellier | 34295 | France |
| Pfizer Investigational Site | Nancy | 54000 | France |
| Pfizer Investigational Site | Nice | Cedex 06002 | France |
| Pfizer Investigational Site | Paris | 75019 | France |
| Pfizer Investigational Site | Paris | 75651 | France |
| Pfizer Investigational Site | Paris | 75674 | France |
| Pfizer Investigational Site | Strasbourg | 67091 | France |
| Pfizer Investigational Site | Toulouse | 31043 | France |
| Pfizer Investigational Site | Tours | 37044 | France |
| Pfizer Investigational Site | Katowice | 40-635 | Poland |
| Pfizer Investigational Site | Krakow | 31-523 | Poland |
| Pfizer Investigational Site | Lublin | 27-718 | Poland |
| Pfizer Investigational Site | Warsaw | 00-416 | Poland |
| Pfizer Investigational Site | Warsaw | 02-097 | Poland |
| Pfizer Investigational Site | Warsaw | 02-957 | Poland |
| Pfizer Investigational Site | Wroclaw | 50-420 | Poland |
| Pfizer Investigational Site | Braga | 4701-965 | Portugal |
| Pfizer Investigational Site | Coimbra | 3000-075 | Portugal |
| Pfizer Investigational Site | Funchal | 9000-168 | Portugal |
| Pfizer Investigational Site | Lisbon | Portugal |
| Pfizer Investigational Site | Matosinhos Municipality | 4454-509 | Portugal |
| Pfizer Investigational Site | Ponta Delgada | 9500-370 | Portugal |
| Pfizer Investigational Site | Ponta Delgada | 9500 | Portugal |
| Pfizer Investigational Site | Porto | 4099-001 | Portugal |
| Pfizer Investigational Site | Lausanne | CH-1011 | Switzerland |
| Pfizer Investigational Site | Zurich | CH-8008 | Switzerland |
| Pfizer Investigational Site | Zurich | CH-8091 | Switzerland |
| ID | Term |
|---|---|
| D012640 | Seizures |
| D004827 | Epilepsy |
| ID | Term |
|---|---|
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069583 | Pregabalin |
| ID | Term |
|---|---|
| D005680 | gamma-Aminobutyric Acid |
| D000613 | Aminobutyrates |
| D002087 | Butyrates |
| D000144 | Acids, Acyclic |
| D002264 | Carboxylic Acids |
| D009930 | Organic Chemicals |
| D000596 | Amino Acids |
| D000602 | Amino Acids, Peptides, and Proteins |
Not provided
Not provided